ANGPT2 and neoplasm: We also observed ECs with increased angiogenic activity driven by tumor-mediated VEGF-VEGFR activated pathway network involving PVLAP and ANGPT2 in the endothelium with a concomitant reduction in immune activity during non-solid to solid disease progression.